Back to top

Analyst Blog

Genomic Health, Inc. (GHDX - Analyst Report) recently announced the presentation of results from multiple Oncotype DX breast cancer studies at the 9th European Breast Cancer Conference (EBCC-9), scheduled from March 19 to 21 in Glasgow, Scotland, U.K. 

The data to be presented is expected to draw attention toward the need for greater availability of a standard predictive genomic testing, like Oncotype DX, to promote more informed chemotherapy treatment decisions in early-stage breast cancer patients in Europe. 

The Oncotype DX breast cancer test is the only multigene expression test that is commercially available. It is also supported by clinical evidence that validates its ability to predict the likelihood of chemotherapy benefits as well as recurrence in early-stage breast cancer. The Oncotype DX gene expression assay is designed for women with early-stage (stage I or II), node-negative, estrogen receptor-positive (ER+) invasive breast cancer prescribed to be treated with therapy.

After a thorough research on Oncotype DX breast cancer test, comprising almost 16 studies conducted with 1,766 patients, it can be concluded that Oncotype DX has successfully demonstrated its clinical utility and cost effectiveness. 

Genomic Health has earlier presented results from multiple studies propagating the benefits of Oncotype DX test in conferences like the 2014 American Society of Clinical Oncology Gastrointestinal Cancer (ASCO GI) Symposium and the 36th Annual CTRC-AACR San Antonio Breast Cancer Symposium.

Owing to increased popularity of the Oncotype DX test among physicians, Genomic Health experienced a 15% rise in the test volume to more than 85,000 tests in 2013. Management also estimates the adoptability of the tests to further increase to 98,000–102,500 tests in 2014.

Currently, Genomic Health carries a Zacks Rank #4 (Sell). Some better-ranked stocks in the broader healthcare sector worth considering are Alexion Pharmaceuticals, Inc. (ALXN - Analyst Report), Alkermes plc (ALKS - Analyst Report) and ANI Pharmaceuticals, Inc. (ANIP - Snapshot Report). All these stocks sport a Zacks Rank #1 (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
PLANAR SYST… PLNR 4.38 +3.79%
BITAUTO HOL… BITA 80.47 +3.53%
CHINA BIOLO… CBPO 47.65 +2.74%
YY ADS YY 87.88 +2.48%
MALLINCKROD… MNK 72.63 +2.41%